BR112016006485A2 - composições de liberação pulsátil revestidas por compressão - Google Patents

composições de liberação pulsátil revestidas por compressão

Info

Publication number
BR112016006485A2
BR112016006485A2 BR112016006485A BR112016006485A BR112016006485A2 BR 112016006485 A2 BR112016006485 A2 BR 112016006485A2 BR 112016006485 A BR112016006485 A BR 112016006485A BR 112016006485 A BR112016006485 A BR 112016006485A BR 112016006485 A2 BR112016006485 A2 BR 112016006485A2
Authority
BR
Brazil
Prior art keywords
compression
active pharmaceutical
pharmaceutical ingredient
delayed release
release compositions
Prior art date
Application number
BR112016006485A
Other languages
English (en)
Inventor
Lee Der-Yang
Por Li Shun
Kutch Timothy
Original Assignee
Johnson & Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer Inc filed Critical Johnson & Johnson Consumer Inc
Publication of BR112016006485A2 publication Critical patent/BR112016006485A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção é dirigida a uma forma de dosagem que compreende uma porção de liberação imediata de um primeiro ingrediente farmacêutico ativo e uma porção de liberação retardada de um segundo ingrediente farmacêutico ativo, sendo que (a) a porção de liberação imediata compreende de cerca de 1 mg a cerca de 1.000 mg do primeiro ingrediente farmacêutico ativo; e (b) a porção de liberação retardada compreende de cerca de 1 mg a cerca de 1.000 mg do segundo ingrediente farmacêutico ativo; sendo que a porção de liberação retardada é revestida com um revestimento de liberação retardada compreendendo pelo menos um polímero erodível dilatável e uma carga, e sendo que a porção de liberação imediata está em contato com o revestimento de liberação retardada.
BR112016006485A 2013-09-27 2014-09-26 composições de liberação pulsátil revestidas por compressão BR112016006485A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361883590P 2013-09-27 2013-09-27
US201462030310P 2014-07-29 2014-07-29
PCT/US2014/057822 WO2015048521A1 (en) 2013-09-27 2014-09-26 Compression coated pulsatile release compositions

Publications (1)

Publication Number Publication Date
BR112016006485A2 true BR112016006485A2 (pt) 2017-08-01

Family

ID=51691182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006485A BR112016006485A2 (pt) 2013-09-27 2014-09-26 composições de liberação pulsátil revestidas por compressão

Country Status (10)

Country Link
US (1) US20150093439A1 (pt)
EP (1) EP3049069A1 (pt)
KR (1) KR20160058944A (pt)
CN (1) CN105579033A (pt)
AU (1) AU2014324704A1 (pt)
BR (1) BR112016006485A2 (pt)
CA (1) CA2924722A1 (pt)
HK (1) HK1224207A1 (pt)
RU (1) RU2016116271A (pt)
WO (1) WO2015048521A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201462A1 (en) * 2020-11-13 2022-05-19 Bayer Healthcare Llc Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
WO2007073702A2 (es) * 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
LT2596784T (lt) * 2007-11-23 2017-03-27 Grünenthal GmbH Tapentadolio kompozicijos
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
CN102160855B (zh) * 2011-03-30 2013-01-23 吴家安 右旋布洛芬缓释片及制备方法
CN202314482U (zh) * 2011-08-03 2012-07-11 天津市嵩锐医药科技有限公司 布洛芬定时释药三层片

Also Published As

Publication number Publication date
CN105579033A (zh) 2016-05-11
RU2016116271A (ru) 2017-11-01
US20150093439A1 (en) 2015-04-02
AU2014324704A1 (en) 2016-04-07
RU2016116271A3 (pt) 2018-06-01
KR20160058944A (ko) 2016-05-25
CA2924722A1 (en) 2015-04-02
HK1224207A1 (zh) 2017-08-18
EP3049069A1 (en) 2016-08-03
WO2015048521A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112018067586A2 (pt) composição administrável oralmente
BR112016000194A8 (pt) forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
MX340591B (es) Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
BR112015011430A2 (pt) composição para liberação imediata e prolongada
HRP20191489T1 (hr) Kombinirani sastav
BR112017028048A2 (pt) drospirenona como o único ingrediente contraceptivo para uso
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
BR112018068116A2 (pt) película transmucosal para administração de montelucaste
CY1123933T1 (el) Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης
BR112015030350A2 (pt) forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular
BR112015020307A2 (pt) formulação de cápsula rígida
BR112016006485A2 (pt) composições de liberação pulsátil revestidas por compressão
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
AR096223A1 (es) Pastilla de nicotina para administración oral
BRPI1010987B8 (pt) composições de dosagem sólida de liberação controlada contendo ibuprofeno
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CR20180209A (es) Formulación de liberación modificada de naproxeno sodico
BR112016026422A2 (pt) solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2533 DE 23-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.